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Abstract Gelsolin, an actin-modulating protein, derived from a 
single gene exists in intracellular and secreted forms. A point 
mutation at position 187 of both forms of gelsolin causes familial 
amyloidosis of the Finnish type (FAF). Here, we expressed both 
isoforms of the wild-type and FAF mutant gelsolin in mouse 
embryonic gelsolin-null fibroblasts. We demonstrate that the 
FAF mutation does not interfere with the normal actin- 
modulating function of intracellular gelsolin, and that aberrant 
processing of secreted FAF gelsolin to FAF amyloid precursor 
takes place in the gelsolin-negative background. These results 
suggest hat, in patients with FAF, symptoms are caused by the 
accumulation in their tissues of amyloid derived from plasma 
gelsolin and are not due to functional differences in cytoplasmic 
gelsolin. 
© 1999 Federation of European Biochemical Societies. 
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1. Introduction 
Gelsolin is a widely expressed protein which exists in se- 
creted and intracellular forms, both of which are encoded 
by a single gene on chromosome 9 [1 3]. Secreted gelsolin 
differs from intracellular gelsolin in having a signal peptide, 
a 25-residue amino-terminal extension and a disulphide bond 
between cysteines 188 and 201 [1,4]. The major function of 
intracellular gelsolin is participation i and regulation of actin 
filament dynamics for motility. In vitro, gelsolin severs iso- 
lated actin filaments, which results in their rapid shortening. 
After severing the filaments, gelsolin binds to their barbed 
ends, preventing their elongation. Gelsolin can also nucleate 
growth of actin filaments from monomers, the result being 
formation of short actin filaments. Binding of gelsolin to 
phosphoinositides (PPIs) removes gelsolin from the actin fila- 
ment ends, providing a site for rapid addition of actin mono- 
mers [5 8]. Intracellular gelsolin participates in regulation of 
the architecture, motility and movement of the cells [9]. Se- 
creted gelsolin has been thought o have a major function in 
scavenging actin and in clearance of F-actin from the blood- 
stream after tissue injury, but may also function as a lipid 
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carrier [10 12]. Recently, it was reported that secretory gelso- 
lin can bind to amyloid-[3 protein (A[3) suggesting that it could 
have a role in the binding and sequestration of A]3 in the 
plasma and cerebrospinal fluid [13]. Gelsolin-null mice are 
viable, but have defects in platelet activation during haemo- 
stasis, the inflammatory response and the dermal fibroblast 
function in vivo, and serum fi'om these mice is unable to sever 
actin filaments [14]. 
Amyloidoses are a heterogeneous group of disorders in 
which abnormal fibrillar protein deposits derived from differ- 
ent proteins accumulate in patients' tissues [15]. A mutation at 
position 187 of intracellular nd secretory gelsolin (numbering 
based on secretory gelsolin) results in gelsolin-related amy- 
loidosis or familial amyloidosis of the Finnish type (FAF) 
[16-18]. This mutation leads to accumulation of internal pep- 
tides of gelsolin (FAF amyloid) in the tissues [19,20]. FAF is 
an autosomal, dominantly inherited amyloid polyneuropathy, 
characterised by corneal attice dystrophy, progressive cranial 
and peripheral neuropathy and skin changes. Most of the 
patients are heterozygous for the FAF mutation and the pro- 
gression of the disease in them is slow over several decades 
while homozygosity is associated with early onset of the dis- 
ease and more severe clinical findings [21-23]. Mutant secre- 
tory FAF gelsolin (Asn/Tyrls7) is cleaved in various cell types 
to an aberrant 68-kDa FAF amyloid precursor fragment con- 
sisting of amino acids 173-755 of gelsolin. This abnormal 
processing of mutant secretory gelsolin is probably due to 
lack of the disulphide bond normally formed next to the 
FAF mutation site between cysteine residues 188 and 201 of 
gelsolin. A second putative cleavage of mutant secretory gel- 
solin at amino acid residue 244 is required to generate the 
FAF amyloid protein (amino acid residues 173~44 of gelso- 
lin) accumulating in patients' tissues [19,20,24,25]. In contrast, 
intracellular gelsolin bearing the FAF mutation is not aber- 
rantly cleaved in COS-1 cells, which suggests that the secre- 
tory form of gelsolin is the source of amyloid in FAF [26]. 
Although, according to transient expression analyses, proc- 
essing of intracellular mutant FAF gelsolin appears to be 
normal, the consequences of the FAF mutation for the func- 
tioning of gelsolin are controversial. Dysfunction of the mu- 
tant FAF gelsolin might have pathological consequences via 
disturbed interactions with actin, the major intracellular pro- 
tein of the body. In one report, the serum of a patient homo- 
zygous for the FAF mutation appeared to have reduced func- 
tional activity of gelsolin [27]. Here, we use viral vectors to 
express the two isoforms of the wild-type and FAF mutant 
gelsolin in embryonic fibroblasts derived from gelsolin knock- 
out mice [14]. These cells provided us with an ideal environ- 
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ment for studying the actin-modulating function of mutant 
FAF  gelsolin in vivo and for characterising the processing 
of the mutant  protein without the interference of endogenous 
gelsolin. 
2. Materials and methods 
2.1. Cell lines and cultures 
GSN / embryonic mouse fibroblasts (GSN EF) were derived 
from embryos of gelsolin knock-out mice [14]. GSN-EF cells were 
cultured on dishes coated with 50 ~tg/ml (Sigma) poly-D-lysine and 
maintained in Dulbecco's modified Eagle's medium (DMEM) supple- 
mented with 15% foetal bovine serum (FBS) (Hyclone). Embryonic 
AGA / mouse fibroblasts (AGA EF) were derived from El4 em- 
bryos of mice with homozygous targeted isruption of the aspartyl- 
glucosaminidase g ne [28]. AGA EF cells were cultured on dishes 
coated with 0.1% gelatin and maintained in DMEM supplemented 
with 15% FBS. Primary human fibroblasts, NIH 3T3, CREBAG2 
and COS-1 cells were cultured in DMEM supplemented with 10% 
FBS. qz CRIP cells were grown in DMEM with 10% newborn calf 
serum [29]. All media were supplemented with 2 mM L-glutamine and 
100 IU/ml penicillin and 50 mg/ml streptomycin. HPV16 E6/E7 rep- 
lication-defective retrovirus and the packaging cell line for immortal- 
isation of mouse embryonic fibroblasts were kindly provided by Dr 
Denise A. Galloway and Dr Anu Wartiovaara. 
2.2. Construction o/" recombhutnt retroviruses 
cDNAs encoding both secretory and intracellular wild-type (G654) 
and FAF mutant (G654A) gelsolin were obtained from pCD-X vector 
constructs [24,26] and subcloned into the BamHI site of the Moloney 
murine leukaemia virus-based retrovirus vector pM48, containing the 
phosphoglycerate kinase promoter (PGK-1) [30] (Fig. 1). The correct 
orientations of the gelsolin cDNAs were confirmed by DNA sequenc- 
ing. The gelsolin pM48 constructs were cotransfected into the ~p CRIP 
amphotropic packaging cells with pSV2neo vector by lipol,ectin trans- 
fection [31] and the transfected cells were selected with 500 ~tg/ml of 
G418 (Geneticin). Resistant colonies were isolated and clones produc- 
ing recombinant retroviruses were preliminarily identified with PCR, 
using primers located in the vector PGK-I promoter (5'-GAC CAC 
TGA TAT CCT GTC TTT AAC-3') and in the gelsolin cDNA (5'- 
GAG GCA GAG AAG ACG GGG GC-3') and Western analysis, 
using the monoclonal anti-gelsolin antibody (Sigma) (see Fig. 1). The 
best virus-producing clones were further selected by infecting NIH3T3 
or COS-1 cells grown on 6-well plates with 600 j J1 of the virus super- 
natant in the presence of 8 Jag/ml polybrene (hexadimethrine bromide, 
Sigma) followed by Western analysis of culture supernatants with 
monoclonal anti-gelsolin antibody. The best producer clones (R- 
iGSNwt, R-iGSNAsn187, R-sGSNwt. R-sGSNAsn187) were ex- 
panded and the virus supernatants were filtered through a 0.44flJm 
pore size filter. The absence of the replication-competent retrovirus 
was confirmed by a virus mobilisation assay in CREBAG2 cells, as 
described [32]. As a control for retroviral infections, we used the AGA 
retrovirus, which was a generous gift from Dr Minna Laine (unpub- 
lished data). 
2.3. Gelsolin gene tran~sfer 
Supernatants t¥om the best producer clones (R-iGSNwt, R- 
iGSNAsn187, R-sGSNwt, R-sGSNAsnI87) were used to infect 
GSN EF and AGA EF cells. Semi-confluent cells were infected 
10 times at half-day or daily intervals with 3 ml of the virus super- 
natant and 1.5 ml of cell growth medium in the presence of 8 jag/ml 
polybrene per 10-cm culture dish. The transduced cells were main- 
tained in growth medium for several passages. For Western analysis, 
cells were incubated overnight in serum-fi'ee medium and the super- 
natant was analysed by SDS-PAGE and blotted. Supernatants were 
concentrated with Centricon-3 (Amersham). The cells were detached 
by trypsinisation, and pelleted and lysed in Laemmli sample buffer. 
To inhibit proteases, EDTA (1.2 mg/ml) and PMSF (1 filM) were 
added to the supernatants and cell lysates. 
The construction of the recombinant wild-type (G654) and FAF 
mutant (G654A) adenoviruses (Ad-sGSNwt, Ad-sGSNAsn187) has 
been described earlier [25]. COS-1 cells were infected with these re- 
combinant adenoviruses for 1 h in serum-free medium as described 
[251. 
2.4. hmTmnological techniques 
Monoclonal anti-gelsolin (GS-2C4) (Sigma), monoclonal anti-cc-ac- 
tin (Amersham) and Oregon green 488 phalloidin (Molecular Probes) 
were used at the dilutions provided by the manufacturer. Monoclonal 
anti-gelsolin antibody recognises a 47-kDa peptide derived from a 
chymotryptic cleavage of gelsolin extending to the carboxy-terminus 
of the protein [33]. Polyclonal COOH961 antibody is targeted against 
the carboxy-terminal portion of gelsolin, amino acid residues 420 755. 
Polyclonal AM904 antibody (Anti-am) is targeted against he amy- 
loid-forming region of the gelsolin, amino acids 173 244, and poly- 
clonal NH951 antibody is targeted against he amino-[erminal portion 
of the gelsolin amino acids 1 172 [24-26] (Fig. 1). 
Western blotting was performed as described [24]. When monoclo- 
nal anti-gelsolin antibody was used, 1% goat serum was added to the 
secondary antibody. 
For immunofluorescence analysis, cells grown on poly-D-lysine- 
coated coverslips were fixed with 4% paraformaldehyde for 30 min, 
washed three times with PBS and permeabilised for 15 min in block- 
ing buffer (0.2% saponin and 0.5% BSA in PBS). This was followed by 
incubation for 1 h at room temperature in the blocking buffer con- 
taining COOH961 antibody in 1:1000 dilution. After rinsing with 
blocking buffer, the cells were incubated in the buffer with rhod- 
amine-conjugated goat anti-rabbit IgG (Immunotech) in the presence 
of 10% goat serum for 1 h. To visualise the actin filaments, the cells 
were stained with 5 Ial Oregon green 488 phalloidin in the blocking 
buffer, mounted in GelMount (Biomeda) and viewed with a Leica 
DMR confocal microscope, using a 63 × objective. 
To characterise the actin filaments, three different categories of 
actin filament were visually estimated: (1) cells containing few if 
any actin filaments, (2) cells containing weak filaments, (3) cells con- 
taining strong prominent actin filaments (see Fig. 2). To analyse the 
actin filament staining in the different cell lines, at least 150 non- 
transduced or transduced GSN-EF cells expressing intracellular and 
secretory wild-type and FAF mutant gelsolin were counted by immu- 
nofluorescence microscopy. 
3. Results 
3.1. The celhdar distribution of  gelsolin in GSN-  mouse 
fibroblasts 
In order to study the cellular distribution of gelsolin, em- 
bryonic mouse fibroblasts derived from gelsolin-null mice 
(GSN EF) were infected with recombinant retroviruses en- 
coding either the wild-type or the FAF  mutant  forms of intra- 
cellular and secretory gelsolin (R-iGSNwt, R- iGSNAsn187, 
R-sGSNwt, R-sGSNAsn187) (see Fig. 1) [14]. As a conse- 
quence of a retroviral gene transfer, the recombinant gene 
integrates into the genome of the infected cells. As shown in 
Fig. 3, the GSN EF cells, when transduced with either wild- 
type or FAF  mutant  intracellular or secretory gelsolin, ex- 
pressed gelsolin polypeptides equally. 
Immunofluorescence microscopy with a polyclonal anti- 
body (COOH961) recognising the carboxy-terminal part of 
gelsolin was used to analyse the distribution of wild-type 
and FAF  mutant  gelsolin polypeptides in the transduced cells. 
Intracellular wild-type gelsolin was present primarily in a peri- 
nuclear distribution and was seen throughout  he cytoplasm 
more faintly. A similar staining pattern was observed in cells 
expressing the intracellular FAF  mutant  gelsolin, showing 
that the distribution of the wild-type and FAF  mutant  intra- 
cellular gelsolin in these cells were identical (Fig. 2A,C). The 
majority of the transduced cells showed gelsolin-positive im- 
munofluorescence staining, whereas in the non-transduced 
cells there was a faint non-specific background staining (Fig. 
2I). 
In the GSN-EF  cells expressing the secretory form of wild- 
type gelsolin, gelsolin staining was mainly perinuclear. The 
gelsolin immunostaining of FAF  mutant  secretory gelsolin- 
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Fig. 1. Schematic representation of the secretory and intracellular gelsolin polypeptides and the target regions f gelsolin-specific antibodies 
used in Western blot analyses. The intracellular and secretory wild-type and FAF mutant gelsolin cDNAs were inserted into a Moloney routine 
leukaemia virus-based retrovirus vector pM48 under the control of the phosphoglycerate kinase promoter [30]. The translation initiation me- 
thionines for intracellular (Met25) and secretory (Met 27)gelsolin are shown [45]. NH2 fragment: the 25-kDa amino-terminal cleavage fragment 
of secretory FAF gelsolin found in cell cultures [25]; FAF amyloid: the 8 12-kDa FAF amyloid fragment found in tissues of patients [19,20]; 
GSN-c68: the 68-kDa carboxy-terminal fragment of secretory FAF gelsolin, also called the FAF amyloid precursor [24]. The gelsolin fragments 
used for raising of antisera re also shown. 
transduced cells was identical to that of wild-type cells (Fig. 
2E,G). 
3.2. The effect of  FAF  mutation on the actin network 
Gelsolin is a multifunctional actin-modulating protein 
which has an important role inside the cell. Here we analysed 
whether the FAF mutation could disturb the normal actin- 
modulating function of gelsolin. The GSN-EF cells were in- 
fected with recombinant retroviruses encoding either the 
wild-type or FAF mutant forms of intracellular nd secretory 
gelsolin. As a control we used embryonic fibroblasts 
derived from AGA knock-out mice (AGA-EF), which show 
endogenous expression of gelsolin [28]. The actin network 
of the non-transduced and transduced cells was monitored 
by staining with fluorescein-conjugated Oregon green 488 
phalloidin. 
In the control AGA-EF  cells transduced with a recombi- 
nant retrovirus encoding the AGA cDNA, the actin fibres 
were similar in the non-transduced and transduced cells 
(data not shown). In the non-transduced GSN-EF cells the 
majority of the actin fibres were organised as characteristic 
stress fibres while a minority (about 15%) of the cells con- 
tained very few, if any organised actin filaments (Fig. 2J,K). 
In contrast, in GSN EF cells transduced with the wild-type 
intracellular gelsolin cDNA, about 70% of the cells revealed 
weaker staining of actin fibres or only a few organised actin 
filaments (Fig. 2B). In the GSN EF cells transduced with the 
FAF mutant intracellular gelsolin, the actin fibre staining was 
similar to that in the wild-type gelsolin-transduced lls (Fig. 
2D). The actin monomer staining of non-transduced and 
transduced cells was similar (data not shown). Further, in 
50% of the secretory gelsolin-transduced lls the actin fibres 
were less organised or weaker than in the non-transduced 
GSN-EF cells (Fig. 2F,H,J,K). This was probably due to 
the synthesis of intracellular gelsolin polypeptides from the 
mRNA for secretory gelsolin by a leaky scanning mechanism 
of translation i itiation [34] (see Fig. 1). This was confirmed 
by in vitro transcription-translation of cDNA for secretory 
gelsolin, where, in addition to the full-length 83-kDa secretory 
gelsolin, a faint signal of 80 kDa corresponding to the size of 
the intracellular form of gelsolin was detected (data not 
shown). Thus, introduction of either recombinant wild-type 
or FAF mutant gelsolin in GSN-EF cells seemed to lead in 
both cases to partial disruption of the organised actin fibres. 
Since the actin fibre staining of GSN-EF cells expressing 
either the wild-type or FAF mutant gelsolin were similar, 
these results would suggest hat the actin-modulating func- 
tions of the wild-type and the FAF mutant gelsolin are sim- 
ilar. Further, it shows that the FAF mutation does not disturb 
the actin-gelsolin teraction i  these cells. 
3.3. The processing of  mutant FAF  gelsolin in GSN-  
embryonic mouse fibroblasts 
In order to analyse whether the cells lacking gelsolin are 
capable of processing mutant FAF gelsolin to FAF amyloid 
precursor, the retrovirally transduced GSN-EF cells and con- 
trol AGA-EF  cells and their corresponding media were ana- 
lysed by Western blotting. The gelsolin polypeptide staining 
pattern of the cell extracts of transduced GSN EF cells ex- 
pressing intra~cellular wild-type and FAF mutant gelsolin were 
identical. The 80-kDa band corresponding to the intracellular 
full-length gelsolin was detected with monoclonal nti-gelsolin 
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Fig. 2. Confocal images showing the immunofluorescence staining of i tracellular and secretory gelsolin and actin filaments in GSN-EF cells. 
GSN EF cells transduced with retroviral constructs encoding the intracellular wild-type (R-iwt) and FAF mutant (R-iAsn187) gelsolin a d se- 
cretory wild-type (R-swt) andFAF mutant (R-~Asn187) gelsolin were double-stained with gelsolin COOH961 antibody (red, A, C, E, G, I) and 
Oregon green 488 phalloidin (green, B, D, F, H, J, K). Arrow in F: cell containing few if any actin filaments; arrow in J: cell containing weak 
actin filaments; arrow in K: cell containing strong a d prominent actin filaments. Bar =10 lain. 
antibody which recognises the carboxy-terminal p rt of gelso- 
lin (see Fig. 1 for description of the antibodies and Fig. 3A, 
right and middle). Neither polypeptide bands corresponding 
to the size of the FAF amyloid precursor fragment (GSN-c68) 
(Fig. 3A, middle) nor FAF amyloid were detected in the im- 
munoblotting analyses (data not shown). In addition, we did 
not observe any leakage of intracellular gelsolin into the me- 
dium (data not shown). Thus, in the GSN EF cells, the proc- 
essing of the intracellular wild-type and FAF mutant gelsolin 
were identical. 
In contrast o the findings with the intracellular form of 
gelsolin, the wild-type and FAF mutant forms of secretory 
gelsolin in the transduced GSN EF cells were processed if- 
ferently. The wild-type gelsolin was secreted in the full-length 
form (83 kDa), whereas the media of the GSN EF cells ex- 
pressing FAF gelsolin contained, in addition to the full-length 
gelsolin, the FAF amyloid precursor fragment (GSN-c68) and 
the 25-kDa amino-terminal cleavage fragment of mutant gel- 
solin (Fig. 3B,C). GSN-c68 was also detected in the cell ex- 
tracts of the GSN EF cells expressing secretory FAF mutant 
gelsolin (Fig. 3A, left). The size of the GSN-c68 fragment was 
confirmed by SDS-PAGE to be the same in the retroviral and 
the adenoviral expression systems that we used in our earlier 
experiments [25] (Fig. 3B). The 83-kDa secreted form of gel- 
solin was not detected in the cell extracts, possibly because of 
efficient secretion, whereas the 80-kDa intracellular gelsolin 
was occasionally detected from both the wild-type (data not 
shown) and the FAF mutant secretory gelsolin-expressing 
GSN-EF cells (Fig. 3A, left). In the transduced AGA EF 
cells expressing intracellular and secretory FAF gelsolin, the 
processing of FAF gelsolin was similar to that of the 
GSN EF cells. In particular, both the GSN-c68 and the 
25-kDa amino-terminal fragments of gelsolin were found in 
the medium of the secretory FAF mutant gelsolin-transduced 
cells (data not shown). The proportion of GSN-c68 was un- 
expectedly high in the embryonic mouse fibroblasts (45%). We 
earlier analysed the processing of the secreted FAF mutant 
gelsolin in human fibroblasts and showed that FAF gelsolin is 
not cleaved in these cells [25]. To confirm that this earlier 
result was not due to the adenoviral expression system used, 
human fibroblasts were infected with retroviral constructs en-
coding the wild-type and FAF mutant secretory gelsolin. 
However, even in the retrovirally transduced human fibro- 
blasts the mutant FAF gelsolin was not cleaved (data not 
shown). As the GSN EF cells lack gelsolin, these results in- 
dicate that the aberrant processing of mutant secretory FAF 
gelsolin to FAF amyloid precursor does not require the pres- 
ence of the wild-type gelsolin. 
H. Kangas et al./FEBS Letters 454 (1999) 233-239 237 
A B C 
CELLS MEDIA MEDIA 
I I I I I I 
t "  
t-- ,t-- 
. . . .  "O 'O  r J 
N 
O 
-80  kDa - - ~  -83kDa 
..... --~ ~ -68 kDa 
- -~  . . . . .  68 kDa 
-83kDa 
-25kDa 
Anti-gelsolin Anti-gelsolin NH951 
Fig. 3. Processing of intracellular and secretory FAF gelsolin in GSN-EF cells. GSN EF cells transduced with retroviral constructs encoding 
for intracellular wild-type (R-iwt) and FAF mutant (R-iAsn187) and secretory wild-type (R-swt) and FAF mutant (R-~Asn187) gelsolin, and 
also the respective culture media, were subjected to Western blot analysis a d immunostaining with anti-gelsolin (A,B) and NH951 (C) antibod- 
ies. A: The 80-kDa band corresponding to the intracellular gelsolin was found in the cell extracts of both R-iwt- and R-iAsn187-infected 
GSN-EF cells. Left: GSN-c68 polypeptide was found only in the cell extracts of the R-sAsn187-infected GSN EF cells. B: The 83-kDa band 
corresponding to the full-length secretory gelsolin was found in the medium of GSN EF cells expressing the wild-type and FAF mutant secre- 
tory gelsolin, the GSN-c68 polypeptide only i  the culture medium of cells expressing the FAF mutant secretory gelsolin. As a control, COS-1 
cells infected with recombinant adenoviruses encoding for the wild-type (Ad-swt) and FAF mutant (Ad-~Asn187) secretory gelsolin are shown. 
GSN-c68 is indicated by an arrow. C: The cleavage of FAF secretory gelsolin results in the formation, in addition to the GSN-c68, of a 
25-kDa amino-terminal polypeptide (indicated by an arrow), which was found in the medium of R-~Asn187-transduced GSN EF cells. 
4. Discussion 
All eukaryotic species contain actin, which may make up as 
much as 20"/o of total cellular protein of cells. Actin has vital 
roles, for example in maintaining cell structure and motility, 
including the neuronal growth cone motility. Gelsolin has an 
important role in actin dynamics; it is capable of severing 
actin filaments in the presence of calcium and it can nucleate 
the actin filament assembly and block the fast-growing 
(barbed) ends of actin filaments [5-7]. Structural analysis of 
gelsolin has shown that the FAF mutation is located near the 
F-actin binding and severing domain of gelsolin, on gelsolin 
segment 2 [35,36]. Our data on the proteolytic processing of 
mutant FAF gelsolin indicated that intracellular gelsolin is 
not involved in the actual formation of tissue amyloid in 
FAF [26]. Here, to investigate he possibility that intracellular 
FAF gelsolin might interfere in actin function, we analysed 
the actin filaments in transduced GSN EF cells expressing 
either wild-type or FAF mutant gelsolin. 
Analysis by confocal microscopy indicated that, in the em- 
bryonic gelsolin knock-out fibroblasts (GSN EF), wild-type 
and FAF mutant intracellular gelsolin were similarly distrib- 
uted throughout the cytoplasm and around the nucleus. In 
both wild-type and mutant gelsolin-expressing cells, the secre- 
tory form was located near the nucleus. In the majority of the 
non-transduced GSN EF cells, actin-specific staining revealed 
a prominent filament network. In contrast, in the transduced 
GSN-EF cells expressing either the wild-type or the FAF 
mutant intracellular gelsolin, a distinct majority of the cells 
gave only weak signals from actin filaments or had no fila- 
ments at all. Since the actin filament organisation was similar 
in the transduced GSN EF cells, expressing both the wild- 
type and FAF mutant gelsolin, our results appear to indicate 
that the FAF mutation per se does not disturb the actin-mod- 
ulating function of gelsolin. Studies with gelsolin knock-out 
mice and cell cultures derived from these mice have shown 
defects in neutrophil, fibroblast, platelet and hippocampal 
neuronal structure and function, but no major defects in em- 
bryonic development or organ function [14,3741]. The exis- 
tence of several members of the gelsolin family and other 
proteins with partial functional similarity to gelsolin suggests 
that these other proteins would provide functional compensa- 
tion for lack of gelsolin expression or impaired function of 
gelsolin. Yet, in spite of the other activities compensating for 
the putative malfunction of the mutant FAF gelsolin, patients' 
symptoms would be expected to be more severe if the function 
of the mutant FAF gelsolin were impaired. Together, these 
data suggest hat the symptoms of patients with FAF result 
from accumulation of the abnormally cleaved gelsolin matur- 
ing to amyloid in the patients' tissues and not from the dis- 
turbed function f the mutant FAF gelsolin. 
Our result showing that the actin-modulating function of 
mutant FAF gelsolin is not impaired seems to be at variance 
with the results of Weeds et al. [27], who have shown that the 
FAF mutant plasma gelsolin has defective actin-severing and 
-nucleating activity in vitro. It is possible, however, that the 
FAF mutant intracellular and secretory gelsolins have differ- 
ent actin-modulating functions. We postulated earlier that the 
disulphide bond normally formed next to the FAF mutation 
site in the wild-type gelsolin between cysteines 188 and 201 on 
gelsolin segment 2 is unlikely to be present in the secretory 
mutant FAF gelsolin [25]. The lack of the disulphide bond 
would result in abnormal folding of the mutant FAF gelsolin 
and could influence its normal actin-nucleating and -severing 
function in plasma. However, one cannot exclude the possi- 
bility that the defective actin-modulating function of plasma 
gelsolin reported by Weeds et al. [27] was due to abnormal 
fragmentation of the mutant gelsolin in samples they ana- 
lysed. However, we did not measure the actual in vitro ac- 
tin-severing capacity of either intracellular or the secreted 
mutant FAF gelsolin. After tissue injury, actin may be re- 
leased into the bloodstream and interact with components 
of the haemostatic and fibrinolytic systems by binding for 
example to the fibrin clot. Binding of plasma gelsolin to actin 
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can reduce the incorporation of actin into the clot and thus 
aid in the restoration of the homeostatic mechanisms that 
regulate clot formation and dissolution [42]. The fact that 
patients with FAF  have no coagulation defects [22] might 
rather indicate that the function of the secretory FAF  gelsolin 
is unchanged. 
Amyloidoses are a group of diseases in which normally 
soluble and functional human proteins are converted into in- 
soluble amyloid fibrils that accumulate in patients' tissues. To 
date, at least 18 different amyloid proteins have been found in 
humans [43]. The exact mechanism by which amyloid proteins 
are converted into amyloid fibrils is unknown. Proteolytic 
processing of amyloid precursors eems to be a critical patho- 
genic step in many forms of amyloidoses, since the various 
amyloid proteins are peptides produced by proteolysis from 
larger precursor molecules. We show here that the intracellu- 
lar mutant FAF  gelsolin was not aberrantly cleaved in 
GSN-EF  cells. This accords with our earlier results for 
COS-1 cells, suggesting that the intracellular form of mutant 
FAF  gelsolin is not the source of amyloid in FAF  [26]. In 
contrast, the FAF  mutant secretory gelsolin is processed to 
FAF  amyloid precursor in different cell types [24,25]. In the 
GSN-EF  cells, mutant secretory FAF  gelsolin was also aber- 
rantly cleaved to the FAF  amyloid precursor (GSN-c68), 
which was found in both the culture medium and the cell 
extracts of GSN-EF  cells. This is the first time that GSN- 
c68 has been found in the cell extracts of non-neuronal cells. 
In PC12 cells and in vitro differentiated human neuronal pro- 
genitor cells, in contrast to all other types of cells studied so 
far, more than half of the mutant FAF  gelsolin is cleaved to 
the FAF  amyloid precursor [25]. The present finding that al- 
most half of the FAF  gelsolin is also cleaved to FAF  amyloid 
precursor in GSN-EF  cells suggests that a high level or ac- 
tivity of the gelsolin-cleaving enzyme is also present in these 
multipotent embryonic fibroblasts. These clearly differ from 
adult human fibroblasts, indicating the presence of the cleav- 
ing enzyme in embryonic, but not in adult, mesenchymal cells. 
Our finding that proteolytic processing of mutant secretory 
FAF  gelsolin does not require the presence of wild-type gel- 
solin is consistent with the fact that, although almost all of the 
400 FAF  patients are heterozygous for the disease mutation, 
two homozygous patients with FAF  have been reported 
[22,23]. 
In some cases of amyloid diseases, amyloid formation may 
start from the endogenously expressed precursor protein in 
the presence of triggering molecules uch as the amyloid en- 
hancing factor in AA amyloidosis and of prions in prion dis- 
eases [44]. A mechanism of this kind does not seem likely in 
FAF,  where all the available in vitro and in vivo data suggest 
that the mutation at amino acid residue 187 is required and 
sufficient for abnormal initial folding of the FAF  gelsolin and 
for subsequent aberrant proteolytic processing of mutant gel- 
solin to the FAF  amyloid. 
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